Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers

International Journal of Cancer

Volumn 141, Issue 4, 2017, Pages 711-720

  Chu, Yu Ju ^a,b   Yang, Hwai I ^b   Wu, Hui Chen ^c   Liu, Jessica ^b   Wang, Li Yu ^d   Lu, Sheng Nan ^e   Lee, Mei Hsuan ^a   Jen, Chin Lan ^b   You, San Lin ^f   Santella, Regina M ^c   Chen, Chien Jen ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c Department of Medicine   (United States)

^d MACKAY MEDICAL COLLEGE   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

aflatoxin B1 albumin adducts; chronic hepatitis B; cirrhosis; HCC

Indexed keywords

AFLATOXIN B1; ALBUMIN;

ALBUMIN BLOOD LEVEL; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONTROLLED STUDY; ECHOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; VIRUS CARRIER; ADULT; BLOOD; COMPLICATION; FEMALE; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; ODDS RATIO; STATISTICAL MODEL;

ADULT; AFLATOXIN B1; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 85019705576     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30782     Document Type: Article

References (37)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
2. Sakamoto M. Pathology of early hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S135–8.
3. Simonetti RG, Camma C, Fiorello F, et al. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991;36:962–72.
4. Sugimura T. Multistep carcinogenesis: a 1992 perspective. Science 1992;258:603–7.
5. Do AL, Wong CR, Nguyen LH, et al. Hepatocellular carcinoma incidence in noncirrhotic patients with chronic hepatitis B and patients with cirrhosis of all etiologies. J Clin Gastroenterol 2014;48:644–9.
6. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014;12:145.
7. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674–87.
8. Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med 2012;4:19–37.
9. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55.
10. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15 Suppl 4:14–22.
11. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838–51.
12. Chen CJ, Wang LY, Lu SN, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996;24:38–42.
13. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3–10.
14. Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943–6.
15. Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996;67:620–5.
16. Wu HC, Wang Q, Yang HI, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2009;18:846–53.
17. Williams JH, Phillips TD, Jolly PE, et al. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 2004;80:1106–22.
18. Raney VM, Harris TM, Stone MP. DNA conformation mediates aflatoxin B1-DNA binding and the formation of guanine N7 adducts by aflatoxin B1 8,9-exo-epoxide. Chem Res Toxicol 1993;6:64–8.
19. Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 2002;17:471–81.
20. Groopman JD, Zhu JQ, Donahue PR, et al. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res 1992;52:45–52.
21. Wild CP, Hudson GJ, Sabbioni G, et al. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1992;1:229–34.
22. Scholl PF, Groopman JD. Long-term stability of human aflatoxin B1 albumin adducts assessed by isotope dilution mass spectrometry and high-performance liquid chromatography-fluorescence. Cancer Epidemiol Biomarkers Prev 2008;17:1436–9.
23. Kuniholm MH, Lesi OA, Mendy M, et al. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect 2008;116:1553–7.
24. Wild CP, Jiang YZ, Sabbioni G, et al. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res 1990;50:245–51.
25. Chen Y-C, Liao C-D, Lin H-Y, et al. Survey of aflatoxin contamination in peanut products in Taiwan from 1997 to 2011. J Food Drug Anal 2013;21:247–52.
26. Chen M-T, Hsu Y-H, Wang T-S, et al. Mycotoxin monitoring for commercial foodstuffs in Taiwan. J Food Drug Anal 2016;24:147–56.
27. Makarananda K, Pengpan U, Srisakulthong M, et al. Monitoring of aflatoxin exposure by biomarkers. J Toxicol Sci 1998;23 Suppl 2:155–9.
28. Skipper PL, Tannenbaum SR. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis 1990;11:507–18.
29. Amla I, Kamala CS, Gopalakrishna GS, et al. Cirrhosis in children from peanut meal contaminated by aflatoxin. Am J Clin Nutr 1971;24:609–14.
30. Karaman M, Ozen H, Tuzcu M, et al. Pathological, biochemical and haematological investigations on the protective effect of alpha-lipoic acid in experimental aflatoxin toxicosis in chicks. Br Poult Sci 2010;51:132–41.
31. Seffner W, Schiller F, Lippold U, et al. Experimental induction of liver fibrosis in young guinea pigs by combined application of copper sulphate and aflatoxin B1. Toxicol Lett 1997;92:161–72.
32. Wogan GN. Chemical nature and biological effects of the aflatoxins. Bacteriol Rev 1966;30:460–70.
33. Ortatatli M, Oguz H, Hatipoglu F, et al. Evaluation of pathological changes in broilers during chronic aflatoxin (50 and 100 ppb) and clinoptilolite exposure. Res Vet Sci 2005;78:61–8.
34. Wouters AT, Casagrande RA, Wouters F, et al. An outbreak of aflatoxin poisoning in dogs associated with aflatoxin B1-contaminated maize products. J Vet Diagn Invest 2013;25:282–7.
35. Arana S, Alves VA, Sabino M, et al. Immunohistochemical evidence for myofibroblast-like cells associated with liver injury induced by aflatoxin B1 in rainbow trout (Oncorhynchus mykiss). J Comp Pathol 2014;150:258–65.
36. Moudgil V, Redhu D, Dhanda S, et al. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. J Environ Pathol Toxicol Oncol 2013;32:165–75.
37. Jiang Y, Jolly PE, Ellis WO, et al. Aflatoxin B1 albumin adduct levels and cellular immune status in Ghanaians. Int Immunol 2005;17:807–14.